SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $366,571 | +14.5% | 13,296 | +24.9% | 0.00% | 0.0% |
Q2 2023 | $320,079 | -16.2% | 10,648 | +1.0% | 0.00% | 0.0% |
Q1 2023 | $381,792 | -6.5% | 10,538 | -7.9% | 0.00% | 0.0% |
Q4 2022 | $408,172 | +46.8% | 11,443 | +39.3% | 0.00% | 0.0% |
Q3 2022 | $278,000 | +24.1% | 8,214 | +6.0% | 0.00% | 0.0% |
Q2 2022 | $224,000 | -5.5% | 7,746 | -12.8% | 0.00% | – |
Q3 2021 | $237,000 | +1.3% | 8,887 | -0.6% | 0.00% | – |
Q1 2021 | $234,000 | -80.8% | 8,942 | -81.5% | 0.00% | -100.0% |
Q4 2020 | $1,216,000 | -13.8% | 48,327 | -28.6% | 0.00% | 0.0% |
Q3 2020 | $1,411,000 | -29.1% | 67,701 | -19.1% | 0.00% | -33.3% |
Q2 2020 | $1,989,000 | +146.8% | 83,735 | +86.9% | 0.00% | +200.0% |
Q1 2020 | $806,000 | +96.1% | 44,810 | +199.7% | 0.00% | – |
Q3 2019 | $411,000 | -38.7% | 14,950 | -26.2% | 0.00% | -100.0% |
Q2 2019 | $670,000 | +25.7% | 20,250 | +33.0% | 0.00% | 0.0% |
Q1 2019 | $533,000 | +6.6% | 15,224 | +1.2% | 0.00% | 0.0% |
Q4 2018 | $500,000 | -69.6% | 15,049 | -53.9% | 0.00% | -50.0% |
Q3 2018 | $1,645,000 | -67.4% | 32,666 | -61.3% | 0.00% | -60.0% |
Q2 2018 | $5,046,000 | -17.4% | 84,316 | -36.8% | 0.01% | -28.6% |
Q1 2018 | $6,109,000 | +81.9% | 133,388 | +58.2% | 0.01% | +75.0% |
Q4 2017 | $3,359,000 | -4.2% | 84,291 | -3.8% | 0.00% | 0.0% |
Q3 2017 | $3,505,000 | -5.8% | 87,629 | +1.5% | 0.00% | -20.0% |
Q2 2017 | $3,722,000 | +31.9% | 86,364 | -4.2% | 0.01% | +25.0% |
Q1 2017 | $2,822,000 | +37.1% | 90,166 | +10.6% | 0.00% | +33.3% |
Q4 2016 | $2,058,000 | -21.1% | 81,494 | -22.7% | 0.00% | -25.0% |
Q3 2016 | $2,607,000 | -14.2% | 105,406 | -29.3% | 0.00% | -20.0% |
Q2 2016 | $3,038,000 | +16.4% | 149,156 | -12.8% | 0.01% | 0.0% |
Q1 2016 | $2,609,000 | +32.7% | 171,070 | +16.9% | 0.01% | +66.7% |
Q4 2015 | $1,966,000 | -33.9% | 146,330 | -31.0% | 0.00% | -50.0% |
Q3 2015 | $2,975,000 | +11.6% | 212,039 | +35.1% | 0.01% | +20.0% |
Q2 2015 | $2,665,000 | +65.1% | 156,946 | +17.6% | 0.01% | +25.0% |
Q1 2015 | $1,614,000 | +6.2% | 133,471 | -27.1% | 0.00% | +33.3% |
Q4 2014 | $1,520,000 | +128.2% | 183,171 | +139.1% | 0.00% | +50.0% |
Q3 2014 | $666,000 | -33.3% | 76,600 | -16.0% | 0.00% | -33.3% |
Q2 2014 | $999,000 | – | 91,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |